All In Biotech

NDA 020727 · Azurity

Bidil

Hydralazine Hydrochloride, Isosorbide Dinitrate · Oral · Nitrate Vasodilator

Last checked: Nov 20, 2026Latest source record: Jan 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 23, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

14 Phase 3, 4 recruiting

FAERS reports

429

303 serious, 66 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2025.

BiDil is a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) 1.1 Treatment of Heart Failure in Self-identified Black Patients BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. 1.2 Limitations of Use There is little experience in patients with NYHA class IV heart failure.

Mechanism: The mechanism of action underlying the beneficial effects of BiDil in the treatment of heart failure has not been established. Isosorbide dinitrate is a vasodilator affecting both arteries and veins. Its dilator properties result from the release of nitric oxide and the subsequent activation of guanylyl cyclase, and ultimate relaxation of vascular smooth muscle. Several well-controlled clinical trials have used exercise testing to assess the anti-anginal efficacy of chronically-delivered nitrates. In the large majority of these trials, active agents were no more effective than placebo after...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BIDIL · HYDRALAZINE HYDROCHLORIDE 37.5MG; ISOSORBIDE DINITRATE 20MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydralazine" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal failure54
  • chronic kidney disease51
  • acute kidney injury42
  • cardiac failure congestive42
  • nausea38
  • dyspnoea37
  • fatigue35
  • diarrhoea33
  • end stage renal disease29
  • headache28
  • dizziness27
  • pain27

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20068
20071
20087
20098
201011
201115
201221
20139
201433
201531
201635
201755
201838
201953
202040
202122
202213
202315
20247
20252
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bidil (Isosorbide Dinit/Hydralazine)

2024 spending

$520K

Beneficiaries

301

923 claims

Per beneficiary

$1,726

$4.17 per unit

View as table
YearSpending
2020$1,586,874
2021$13,915,297
2022$8,826,644
2023$1,632,501
2024$519,595

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 352 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.